Uncategorized

Novartis Keeps Deals Coming With $2B Excellergy Takeover

Published

2 weeks ago

on

The Excellergy acquisition will complement Novartis’ existing allergy profile, anchored by the IgE blocker Xolair that in February 2024 was approved to treat food allergies in children and adults.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version